Liothyronine

Introduction Overview

Generic Name

liothyronine

Brand Name

Cytomel, Triostat

Dosage Form

oral tablet (25 mcg, 5 mcg, 50 mcg)

Drug Class

Thyroid drugs

Pharmacokinetics

Absorption: Liothyronine is rapidly and almost completely absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations occur within approximately 2 to 4 hours post-dose, making liothyronine faster acting than levothyroxine. Its absorption can be influenced by factors such as gastrointestinal pH, presence of food, and coadministration with certain medications like cholestyramine or colestipol, which may bind the drug and reduce bioavailability. Clinical monitoring of thyroid function tests is critical to ensure adequate dosing and absorption.

Distribution: After absorption, liothyronine is extensively bound to plasma proteins, primarily thyroxine-binding globulin, transthyretin, and albumin, which serve as reservoirs and transporters in the circulation. Its volume of distribution reflects its widespread tissue uptake, particularly in highly perfused organs such as the liver, kidneys, heart, and muscles. The hormone crosses cell membranes by active transport mechanisms to exert its intracellular effects.

Metabolism: Liothyronine (T3) undergoes hepatic metabolism primarily through deiodination, conjugation, and deamination. This metabolism inactivates the hormone and facilitates excretion. Unlike levothyroxine (T4), which requires peripheral conversion to T3, liothyronine bypasses this step and acts directly. Hepatic enzyme activity and factors such as concomitant drug use or liver disease can alter liothyronine metabolism, impacting therapeutic efficacy.

Elimination: The elimination half-life of liothyronine is approximately 2.5 days, significantly shorter than that of levothyroxine. It is excreted through hepatic-biliary routes into the feces and to a lesser extent through renal elimination. In patients with compromised liver or kidney function, clearance may be altered, necessitating dose adjustments. Frequent monitoring is warranted during initiation and titration to avoid toxicity or subtherapeutic effects.

Dosage Forms

Available Dosage Forms: Liothyronine is commercially available as oral tablets in strengths of 5 mcg, 25 mcg, and 50 mcg. These precise microgram doses enable fine titration, especially in populations sensitive to thyroid hormone fluctuations such as the elderly or those with cardiac disease.

Dosages for Adults and Adolescents: Dosing for hypothyroidism generally starts at low doses (e.g., 5 mcg to 25 mcg daily) with gradual titration based on clinical response and thyroid function tests (TSH, free T3). Adults with myxedema coma or thyroid suppression may require different initial regimens, sometimes utilizing intravenous formulations under specialist supervision. Pediatric dosing is carefully weight-based, reflecting increased metabolic demands and to mitigate risk of adverse effects.

Specific Patient Populations: In elderly patients or those with cardiovascular disease, lower initial doses and cautious titration are essential to prevent arrhythmias or myocardial ischemia. Pregnant women require careful dose adjustments throughout gestation to maintain euthyroid status for fetal development. Patients with adrenal insufficiency should correct adrenal function prior to initiation to avoid adrenal crisis. Patients with hepatic or renal impairment may need dose modifications and frequent monitoring due to altered pharmacokinetics.

Mechanism Of Action

Liothyronine is a synthetic form of the active thyroid hormone triiodothyronine (T3), which binds to nuclear thyroid hormone receptors in target tissues, facilitating transcriptional regulation of genes essential for metabolic homeostasis. Upon receptor binding, it influences DNA transcription, increasing synthesis of proteins that regulate cellular metabolism.

At the cellular level, liothyronine enhances basal metabolic rate by stimulating oxygen consumption and modulating carbohydrate, lipid, and protein metabolism. It increases the number and activity of mitochondria, elevates Na+/K+-ATPase activity, and promotes thermogenesis. These effects translate clinically into increased energy expenditure, heat production, and overall metabolic upregulation.

Biochemically, liothyronine modulates expression of enzymes involved in growth, development, and differentiation. It plays a critical role in neurodevelopment and cardiac function by influencing myocardial contractility and heart rate. Clinical studies demonstrate its rapid onset compared to levothyroxine, making it advantageous in acute hypothyroid states like myxedema coma.

Comparatively, unlike levothyroxine (T4) which is a prohormone requiring peripheral deiodination to T3, liothyronine is bioactive upon administration, enabling prompt clinical effects. Research supports its use in specific indications demanding rapid hormone replacement or testing thyroid function through suppression protocols.

Pharmacological Actions

Replacement therapy for deficient endogenous thyroid hormone in hypothyroidism.
Regulation of metabolic rate via modulation of mitochondrial oxidative phosphorylation.
Stimulation of protein synthesis and degradation to maintain anabolic-catabolic balance.
Increase in basal metabolic rate leading to enhanced oxygen consumption and thermogenesis.
Enhancement of cardiovascular function by increasing heart rate and myocardial contractility.
Facilitation of normal growth and development processes, especially neurodevelopment.
Rapid onset of action for critical hypothyroid states such as myxedema coma.
Suppression of thyroid stimulating hormone (TSH) for diagnostic thyroid tests and thyroid cancer management.
Promotion of lipolysis and carbohydrate metabolism adjustments.
Influence on enzymatic activity in liver affecting cholesterol and drug metabolism.
Improvement of gastrointestinal motility and function in hypothyroid patients.
Adjustment of skeletal muscle function by promoting energy availability.
Direct nuclear receptor agonist effect to mediate transcriptional changes.
Regulation of neurotransmitter systems impacting mood and cognition.

Therapeutic Or Clinical Uses

Treatment of hypothyroidism due to diminished thyroid hormone production.
Management of myxedema and myxedema coma requiring rapid hormone replacement.
Supportive therapy in thyroid cancer alongside surgery and radioactive iodine.
Diagnostic use in thyroid suppression tests for evaluating thyroid function.
Adjunctive therapy in pituitary TSH deficiency to restore euthyroid state.
Replacement therapy post-thyroidectomy to maintain metabolic homeostasis.
Treatment of patients inadequately responsive to levothyroxine or requiring faster onset.
Use in select cases of congenital hypothyroidism with specific monitoring.
Management of secondary hypothyroidism due to hypothalamic-pituitary axis disorders.
Off-label investigational uses under endocrinologist guidance.
Therapeutic modulation of TSH suppression to reduce tumor recurrence risk in thyroid cancer.
Employment in patients with allergies or intolerances to levothyroxine formulations.
Treatment during pregnancy to optimize maternal and fetal thyroid hormone status.
Supportive management in combined thyroid hormone deficiencies.

Side Or Adverse Effects

Symptoms of thyroid toxicity such as chest pain and palpitations.
Tachycardia and arrhythmias due to overstimulation of cardiac tissue.
Nervousness, irritability, tremors, and anxiety.
Insomnia and sleep disturbances caused by increased metabolism.
Gastrointestinal upset including diarrhea and increased appetite.
Weight loss due to enhanced metabolic rate.
Muscle weakness and fatigue from catabolic effects.
Headaches and dizziness potentially related to systemic hypermetabolism.
Irregular menstrual cycles or menstrual disturbances.
Allergic reactions including rash, hives, and facial swelling.
Sweating and heat intolerance due to increased thermogenesis.
Confusion or neurological symptoms in cases of overdose.
Bone density reduction with long-term overreplacement (risk of osteoporosis).
Potential exacerbation of underlying cardiovascular disease.
Rare occurrence of seizures or vision disturbances associated with toxicity.

Precautions

Use cautiously in patients with coronary artery disease or cardiac arrhythmias.
Monitor thyroid function tests regularly to avoid over- or under-treatment.
Adjust doses carefully in elderly patients to reduce risk of cardiac adverse events.
Evaluate patients for adrenal insufficiency prior to initiating therapy.
In pregnant women, monitor thyroid hormone levels every trimester for dose adjustment.
Avoid abrupt discontinuation to prevent hypothyroid crisis.
Consider dose modification in patients with hepatic or renal impairment.
Patients with bleeding disorders require close monitoring due to potential drug interactions.
Caution advised in patients with osteoporosis given risk of bone resorption.
Initiate therapy at lower doses in pediatric patients with close supervision.
Inform patients about potential interactions with other medications and supplements.
Educate patients on recognizing symptoms of hyperthyroidism and toxicity.
Avoid changing brands without consulting healthcare provider due to bioequivalence variability.
Assess and monitor for drug interactions that reduce absorption or accelerate metabolism.
Use with caution in patients with diabetes mellitus as thyroid hormone can affect glucose metabolism.

Warnings

Do not use liothyronine for treatment of obesity or weight management.
Contraindicated in patients with untreated adrenal gland problems unless corrected.
Immediate medical attention required if symptoms of thyroid toxicity appear (chest pain, rapid heartbeat, sweating).
Increased sensitivity in elderly or cardiovascular disease patients warrants close monitoring.
Excessive dosing can lead to serious cardiovascular side effects including myocardial infarction.
Abrupt withdrawal may precipitate hypothyroidism or myxedema coma in dependent patients.
Potential interaction with anticoagulants necessitates frequent monitoring of coagulation parameters.
Overdose associated with severe neurological and cardiovascular complications.
Avoid sudden changes in dosage formulations or brands without clinical guidance.
Pregnant or breastfeeding women require individualized dosing adjustments and monitoring.
Risk of inducing arrhythmias or angina in patients with pre-existing heart disease.
Use with caution when combined with other stimulatory or metabolic drugs.
Careful patient selection and dose titration required in fragile populations.
Monitor patients with bleeding or clotting disorders closely for adverse effects.
Drug can interfere with results of certain laboratory thyroid function tests.

Contraindication

Untreated adrenal insufficiency or adrenal gland disorders not adequately controlled.
Known hypersensitivity to liothyronine or any component of the formulation.
Use for weight loss or obesity management.
Acute myocardial infarction or severe cardiac insufficiency without close monitoring.
Untreated thyrotoxicosis or hyperthyroid states.
Patients with acute thyrotoxic crisis unless specifically indicated and monitored.
Significant uncorrected hypopituitarism.
Known hypersensitivity to excipients in tablet formulation.
Severe acute systemic illnesses contraindicating thyroid hormone therapy initiation.
Patients with untreated or unstable angina pectoris.
Children with transient hypothyroidism who may not need permanent therapy.
Concurrent use with other thyroid hormone replacement drugs without proper medical supervision.
Use during early stages of treatment for adrenal insufficiency without hormonal correction.
Non-thyroidal illness syndrome where thyroid hormone replacement is not beneficial.
Pregnancy without endocrinologist supervision when dosing and monitoring are unavailable.

Drug Interactions

Cholestyramine, colesevelam, colestipol, and sevelamer reduce liothyronine absorption; separate dosing by at least 4 hours.
Anticoagulants (warfarin, Coumadin, Jantoven) enhanced by liothyronine leading to increased bleeding risk.
Cancer chemotherapeutic agents may alter thyroid hormone metabolism.
Hormone replacement therapies and oral contraceptives can decrease liothyronine levels by increasing thyroid-binding globulin.
Corticosteroids may antagonize effects of thyroid hormones and require dose adjustments.
Antidepressants and seizure medications can modify thyroid hormone metabolism or clearance.
Insulin and oral antidiabetic drugs may require dose modifications as liothyronine alters glucose metabolism.
Certain cold and cough remedies may interfere with liothyronine effectiveness.
Drugs altering liver enzyme activity (e.g., phenytoin, carbamazepine) can affect liothyronine metabolism.
High doses of salicylates and nonsteroidal anti-inflammatory drugs displace thyroid hormones from plasma proteins.
Amiodarone, due to iodine content, may affect thyroid hormone synthesis and metabolism, interacting with liothyronine.
Estrogens increase thyroid-binding globulin, potentially altering free liothyronine levels.
Rifampin and phenobarbital accelerate metabolism of thyroid hormones, decreasing liothyronine efficacy.
Calcium and iron supplements may bind liothyronine reducing its absorption; dosing should be separated.
Herbal supplements affecting thyroid function (e.g., soy products, St. John's Wort) can interfere with therapy.

Preparations Of The Drug

Oral tablets available in 5 mcg, 25 mcg, and 50 mcg strengths providing flexibility for dose titration.
Intravenous formulations used in severe hypothyroidism or myxedema coma under specialized care.
Available as branded products: Cytomel and Triostat.
Tablets manufactured to ensure stability and consistent bioavailability.
Liquid formulations are not commonly used but may be compounded in specialized settings for patients with swallowing difficulties.
Commercial preparations include excipients optimized for absorption and minimal adverse effects.
Dosage forms designed for ease of administration in both outpatient and inpatient settings.
Packaging includes clear dosing instructions due to critical importance of correct microgram dosing.
Available in unit-dose packaging for hospital and clinical use to reduce dosing errors.
Products are approved by regulatory agencies with established manufacturing quality standards.
Stable at room temperature, with storage recommendations to avoid moisture and heat degradation.
Preparations typically supplied with medication guides outlining proper use and monitoring parameters.
Some formulations are specifically indicated for thyroid suppression testing and therapeutic use.
Brand formulations differ slightly in excipients but have comparable efficacy when properly monitored.
Parenteral preparations intended strictly for hospital use in acute settings.